Loading…
Decision Guide · channel economics
Every “bagging” debate is really a question about which organization captures the drug margin. Here is the comparison as an economics table instead of a glossary — plus the 2026 payer programs and the 22-state legal map that decide whether you can be forced.
| Channel | Who buys the drug | Who bills the drug | Practice captures | Practice bears |
|---|---|---|---|---|
| Buy-and-bill | Practice | Practice (medical benefit) | Drug margin + administration | Inventory carrying cost, denial/clawback risk, JW-waste exposure |
| White bag | Payer’s specialty pharmacy | Pharmacy (pharmacy benefit) | Administration only | Handling without revenue; stranded patient-specific doses on regimen changes |
| Brown bag | Pharmacy → patient | Pharmacy | Administration only | Integrity/handling risk — most-banned variant (storage chain broken) |
| Clear bag | Practice’s own SP | Affiliated pharmacy | Dispensing margin + administration (in the family) | Pharmacy licensure/ops; payer network access |
The forfeited drug margin is drug-specific — see any drug trend page for the per-dose dollars, or price a specific drug on the calculator.
Two forces decide: state law (11 bans, 11 guardrail states, 6 live bills — every statute cited on the state tracker) and the payer’s program design. The setting distinction matters more than most coverage admits: UHC’s and Anthem’s sourcing mandates bind hospital-outpatient departments, not physician offices; Aetna’s CBM removes listed drugs from the medical benefit on fully-insured plans (with a 12-state carve-out and a biosimilar escape hatch); Cigna’s Pathwell rides on whether the member’s plan carries the benefit. ERISA self-funded plans sit outside every state law.
The most under-used counter: payer programs frequently list the brand but leave same-molecule biosimilars medical-benefit preferred (Aetna lists brand Remicade; Inflectra, Renflexis and Avsola stay). Where the law doesn’t protect you, conversion sometimes does — and the biosimilar’s economics can be better anyway, or catastrophically worse. Check the family table on the relevant drug page before assuming either.
Under buy-and-bill, the practice purchases the drug, stocks it, administers it, and bills the medical benefit — capturing the drug margin plus administration. Under white bagging, a payer-designated specialty pharmacy dispenses the drug for a specific patient and ships it to the practice; the pharmacy bills the drug, and the practice bills administration only.
Brown bagging: the pharmacy dispenses to the patient, who carries the drug to the visit — the most restricted variant because of handling risk. Clear bagging: the practice's own affiliated specialty pharmacy dispenses internally to the site of care — margin stays in the family. Gold bagging: the provider organization dispenses and ships from its own pharmacy ahead of the visit.
Three things: the drug margin on every white-bagged dose (under Medicare math, the effective ~4.3% over ASP; commercial spreads are contract-specific and often larger); scheduling and waste risk — dose changes strand patient-specific inventory, with industry surveys putting white-bag waste in the tens to hundreds of thousands of dollars per site per year; and revenue-cycle complexity, since the practice still bears handling without owning the claim.
Depends on the plan and the state. 11 states currently ban payer white-bag mandates for state-regulated plans and 11 more impose guardrails — but ERISA self-funded plans are exempt everywhere, and the national payers' programs differ sharply by setting (UHC's and Anthem's bind hospital outpatient only; Aetna's CBM moves listed drugs off the medical benefit entirely on fully-insured plans). Check the state tracker for your statute.
When the margin is already gone or negative: a drug underwater at acquisition (some biosimilars), a payer whose contracted rate sits below your acquisition, or volumes too small to justify inventory risk. The decision is drug-by-drug and payer-by-payer arithmetic — not a philosophy.
The reimbursement math behind all of this: ASP+6 after sequestration. Billing mechanics for a white-bagged claim (POS coding, who bills what): CareCost Estimate’s billing references.
The practice X-Ray prices the forfeited margin per drug against your actual mix and payers — and flags where state law or a biosimilar gives you the counter.